|
1
|
Ott JJ, Stevens GA, Groeger J and Wiersma
ST: Global epidemiology of hepatitis B virus infection: New
estimates of age-specific HBsAg seroprevalence and endemicity.
Vaccine. 30:2212–2219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng CY, Chien RN and Liaw YF: Hepatitis B
virus-related decompensated liver cirrhosis: Benefits of antiviral
therapy. J Hepatol. 57:442–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buti M: HBeAg-positive chronic hepatitis
B: Why do i treat my patients with Nucleos(t)ide analogs? Liver Int
34 Suppl. 1:108–111. 2014. View Article : Google Scholar
|
|
4
|
Viganò M, Mangia G and Lampertico P:
HBeAg-negative chronic hepatitis B: Why do I treat my patients with
nucleos(t)ide analogues? Liver Int 34 Suppl. 1:120–126. 2014.
View Article : Google Scholar
|
|
5
|
Yuen MF, Sablon E, Hui CK, Yuan HJ,
Decraemer H and Lai CL: Factors associated with hepatitis B virus
DNA breakthrough in patients receiving prolonged lamivudine
therapy. Hepatology. 34:785–791. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rodriguez C, Chevaliez S, Bensadoun P and
Pawlotsky JM: Characterization of the dynamics of hepatitis B virus
resistance to adefovir by ultra-deep pyrosequencing. Hepatology.
58:890–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zoulim F and Locarnini S: Hepatitis B
virus resistance to nucleos(t)ide analogues. Gastroenterology.
137:1593–1608, e1591–1592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liaw YF, Leung N, Guan R, Lau GK, Merican
I, McCaughan G, Gane E, Kao JH and Omata M: Asian-Pacific consensus
update working party on chronic hepatitis B: Asian-Pacific
consensus statement on the management of chronic hepatitis B: A
2005 update. Liver Int. 25:472–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liaw YF, Kao JH, Piratvisuth T, Chan HL,
Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, et al:
Asian-Pacific consensus statement on the management of chronic
hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai CL, Dienstag J, Schiff E, Leung NW,
Atkins M, Hunt C, Brown N, Woessner M, Boehme R and Condreay L:
Prevalence and clinical correlates of YMDD variants during
lamivudine therapy for patients with chronic hepatitis B. Clin
Infect Dis. 36:687–696. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pallier C, Castéra L, Soulier A, Hézode C,
Nordmann P, Dhumeaux D and Pawlotsky JM: Dynamics of hepatitis B
virus resistance to lamivudine. J Virol. 80:643–653. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bozdayi AM, Uzunalimoğlu O, Türkyilmaz AR,
Aslan N, Sezgin O, Sahin T, Bozdayi G, Cinar K, Pai SB, Pai R, et
al: YSDD: A novel mutation in HBV DNA polymerase confers clinical
resistance to lamivudine. J Viral Hepat. 10:256–265. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niesters HG, De Man RA, Pas SD, Fries E
and Osterhaus AD: Identification of a new variant in the YMDD motif
of the hepatitis B virus polymerase gene selected during lamivudine
therapy. J Med Microbiol. 51:695–699. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liaw YF, Lee CM, Chien RN and Yeh CT:
Switching to adefovir monotherapy after emergence of
lamivudine-resistant mutations in patients with liver cirrhosis. J
Viral Hepat. 13:250–255. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao P, Wang C, Huang L, Xu D and Li T:
Comparison of rescue strategies in lamivudine-resistant patients
with chronic hepatitis B. Antiviral Res. 96:100–104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vassiliadis TG, Giouleme O, Koumerkeridis
G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N,
Mpoumponaris A, Gkisakis D, Theodoropoulos K, et al: Adefovir plus
lamivudine are more effective than adefovir alone in
lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year
study. J Gastroenterol Hepatol. 25:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM,
Lee HC, Chung YH, Lee YS, Yoo W and Kim SO: Increased risk of
adefovir resistance in patients with lamivudine-resistant chronic
hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Hepatology. 43:1385–1391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ,
Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE and Byun KS: Comparison of
lamivudine plus adefovir therapy versus entecavir with or without
adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin
Gastroenterol. 48:889–895. 2014.PubMed/NCBI
|
|
19
|
Lok AS and McMahon BJ: Chronic hepatitis
B. Hepatology. 45:507–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goodman ZD: Grading and staging systems
for inflammation and fibrosis in chronic liver diseases. J Hepatol.
47:598–607. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
World Medical Association: World Medical
Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee GH, Inoue M, Toh JK, Chong RH, Aung
MO, Koay ES and Lim SG: Two-step evolution of the hepatitis B
drug-resistant mutations in a patient who developed primary
entecavir resistance. Liver Int. 33:642–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lok AS, Zoulim F, Locarnini S,
Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M and
Kuiken C: Hepatitis B Virus Drug Resistance Working Group:
Antiviral drug-resistant HBV: Standardization of nomenclature and
assays and recommendations for management. Hepatology. 46:254–265.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ijaz S, Arnold C, Dervisevic S, Mechurova
J, Tatman N, Tedder RS and Naoumov NV: Dynamics of
lamivudine-resistant hepatitis B virus during adefovir monotherapy
versus lamivudine plus adefovir combination therapy. J Med Virol.
80:1160–1170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH,
Choe WH and Lee CH: Clonal evolution of hepatitis B virus
polymerase gene mutations during lamivudine-adefovir combination
treatment. World J Gastroenterol. 18:6437–6446; discussion p 6445.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK,
Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, et al: Resistance to
adefovir dipivoxil in lamivudine resistant chronic hepatitis B
patients treated with adefovir dipivoxil. Gut. 55:1488–1495. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH,
Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, et al: Treatment of
lamivudine-resistant chronic hepatitis B infection: A multicenter
retrospective study. Scand J Gastroenterol. 48:196–204. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD,
Park SH, Lee MS, Park CK, Chae HB, Kim MY, et al: Adding adefovir
vs. switching to entecavir for lamivudine-resistant chronic
hepatitis B (ACE study): A 2-year follow-up randomized controlled
trial. Liver Int. 33:244–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang M, Yuan L, Qiao B and Li Y: Two
rescue therapies in lamivudine-resistant patients with chronic
hepatitis B in the central China: Adefovir monotherapy and adefovir
plus lamivudine. Virus Genes. 48:32–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang ZB, Zhao SS, Huang Y, Dai XH, Zhou
RR, Yi PP, Chen RC, Li WT, Zhang BX, Li N and Fan XG: Comparison of
the efficacy of Lamivudine plus adefovir versus entecavir in the
treatment of Lamivudine-resistant chronic hepatitis B: A systematic
review and meta-analysis. Clin Ther. 35:1997–2006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim HJ, Park JH, Park DI, Cho YK, Sohn CI,
Jeon WK and Kim BI: Rescue therapy for lamivudine-resistant chronic
hepatitis B: Comparison between entecavir 1.0 mg monotherapy,
adefovir monotherapy and adefovir add-on lamivudine combination
therapy. J Gastroenterol Hepatol. 25:1374–1380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pallier C, Rodriguez C, Brillet R,
Nordmann P, Hézode C and Pawlotsky JM: Complex dynamics of
hepatitis B virus resistance to adefovir. Hepatology. 49:50–59.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Villet S, Pichoud C, Billioud G, Barraud
L, Durantel S, Trépo C and Zoulim F: Impact of hepatitis B virus
rtA181V/T mutants on hepatitis B treatment failure. J Hepatol.
48:747–755. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng XL, Li QL and Guo JJ: Dynamics of
lamivudine-resistant hepatitis B virus strains in patients with
entecavir rescue therapy. Virus Genes. 47:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park MS, Kim BK, Kim KS, Kim JK, Kim SU,
Park JY, do Kim Y, Baartarkhuu O, Han KH, Chon CY and Ahn SH:
Antiviral efficacies of currently available rescue therapies for
multidrug-resistant chronic hepatitis B. Clin Mol Hepatol.
19:29–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi
WM, Cho YY, Lee M, Yoo JJ, Cho Y, et al: Efficacy of
entecavir-tenofovir combination therapy for chronic hepatitis B
patients with multidrug-resistant strains. Antimicrob Agents
Chemother. 58:6710–6716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Villet S, Ollivet A, Pichoud C, Barraud L,
Villeneuve JP, Trépo C and Zoulim F: Stepwise process for the
development of entecavir resistance in a chronic hepatitis B virus
infected patient. J Hepatol. 46:531–538. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Villeneuve JP, Durantel D, Durantel S,
Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B,
Trépo C and Zoulim F: Selection of a hepatitis B virus strain
resistant to adefovir in a liver transplantation patient. J
Hepatol. 39:1085–1089. 2003. View Article : Google Scholar : PubMed/NCBI
|
